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Background: Initial levels of highly sensitive cardiac Troponin T (hsTnT) and amino-terminal BNP (NT-proBNP) identify older adults at low-risk for 
cardiovascular events. We hypothesized that the combined trajectories of levels would identify those at-risk for developing an abnormal LVEF (<50%) 
and heart failure (HF).
Methods: NT-proBNP and hsTnT levels were measured at baseline and after 2-3 years in older adults without HF in the Cardiovascular Health 
Study (CHS). In those with low baseline levels (hsTnT< 13 pg/mL, NT-proBNP≤190 pg/mL), a significant rise was defined as: hsTnT >50%; NT-
proBNP > 25% to >190 pg/mL. LVEF was measured at baseline and 5 years. Cox regression estimated the association of change in biomarkers with 
subsequent HF.
Results: Mean age was 73.7 years, with median baseline hsTnT and NT-proBNP levels 3.2 and 73.7 pg/mL. Median follow-up was 11.0 years. 
Those with increases in one or both biomarker levels were older, female, and had more risk factors. The frequency of a new abnormal LVEF and the 
incidence of HF were progressively higher based on the number of biomarker levels that increased (table). The risk of HF persisted across biomarker 
categories after adjustment for baseline levels, demographics and risk factors.
Conclusions: Among older adults with initially low hsTnT and NT-proBNP, the long-term trajectory of change predicts new systolic dysfunction and 
incident HF. Those with increases in both biomarkers are at highest risk, and may be targets for preventative strategies.
New-onset abnormal LVEF and HF admission risk stratified by change in biomarker status
N(%) No Change1322 (65.8)
Increased hsTnT only 297 
(14.8)
Increased NT-proBNP only 
266 (13.2)
Increased hsTnT and NT-
proBNP123 (6.1)
% with abnormal LVEF* 4.0 8.4 6.1 11.8
Incidence rate (HF)** 1.47(1.28-1.70) 2.16(1.67-2.81) 2.80(2.21-3.55) 5.13(3.75-7.03)
Unadjusted 1 [Reference] 1.62(1.25-2.09) 2.00(1.55-2.58) 4.53(3.34-6.14)
Demographics
Adjusted
1 [Reference] 1.37(1.05-1.78) 1.89(1.46-2.45) 3.81(2.79-5.22)
Risk Factor-Adjusted 1 [Reference] 1.37(1.04-1.79) 1.54(1.16-2.05) 3.52(2.53-4.90)
*Among those with normal EF at baseline. **Per 100 person-years.
All Cox models adjusted for baseline biomarker levels. Risk factors include: systolic blood pressure, smoking, heart rate, creatinine, albumin, 
glucose, coronary heart disease, and left ventricular hypertrophy
